Bicara Therapeutics Inc. (BCAX) Dividend History

Bicara Therapeutics Inc. (BCAX) is a biotechnology company focused on developing innovative immuno-oncology therapies. The company specializes in creating targeted treatments that modulate the immune system to combat cancer, leveraging its proprietary platform to develop novel antibody-based therapies.

Dividend History

Bicara Therapeutics Inc. currently does not pay dividends

Company News

Bicara Therapeutics Demonstrates Deep and Durable Responses with Ficerafusp Alfa Plus Pembrolizumab in 1L HPV-Negative R/M HNSCC at ASCO 2025

Bicara Therapeutics presented updated data from its Phase 1/1b clinical trial of ficerafusp alfa in combination with pembrolizumab in patients with first-line recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The data showed deep and durable responses, with a median duration of response of 21.7 months and a median overall survival of 21.3 months.

GlobeNewswire Inc.
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Bicara Therapeutics, a clinical-stage biopharmaceutical company, announced the closing of its $362 million initial public offering on the Nasdaq Global Market under the ticker symbol 'BCAX'.

Benzinga

Page data last updated 08/19/2025 16:49:13 UTC